Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1

Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1

May 26, 2018 Based on a recent planned review, the Data Monitoring Committee (DMC) recommends Phase Ib/II study of daratumumab plus atezolizumab (anti PD-L1 antibody) in patients with previously treated non-small cell lung cancer to be terminated. Phase I MMY2036